Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds

“…Also, Didemnin B was found to induce apoptosis in proliferating lymphocytes and a panel of permanently transformed cell lines [105]. It has also showed potential benefit in a patient with pancreatic adenocarcinoma in a phase I clinical trial [106]. This evidence supported the evaluation of Didemnin B in phase II clinical trials in the U.S., being the first marine product to be approved.…”

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds

“…Also, Didemnin B was found to induce apoptosis in proliferating lymphocytes and a panel of permanently transformed cell lines [105]. It has also showed potential benefit in a patient with pancreatic adenocarcinoma in a phase I clinical trial [106]. This evidence supported the evaluation of Didemnin B in phase II clinical trials in the U.S., being the first marine product to be approved.…”

Clovibactin: Discovery and antimicrobial mechanism of action

“…A relevant clinical aspect to be considered for its potential therapeutic application is the allergenic capacity of depsipeptides in comparison with conventional small molecule drugs. 5,6 In this regard, few immediate and non-immediate hypersensitivity reactions to different cyclic depsipetides, such as didemnin B, 7 pristinamycin IA, 8 and plitidepsin A, 9 have been reported. However, as some of these molecules are administered in combination with other drugs or excipients, in most cases it is unknown to which of the components the reaction is directed.…”

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

“…The first congener of this class, didemnin B, was isolated from the Caribbean tunicate Trididemnum solidum in 1981. Because of poor efficacy and many severe side effects such as anaphylactic reactions and neuromuscular toxicity in phase-I and II trials, its development was abandoned in favor of the second generation didemnin, plitidepsin, more active and better tolerated in clinical studies [154]. Plitidepsin shows in vitro and in vivo anti-tumor activity [35,155,156].…”

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds

“…Also, Didemnin B was found to induce apoptosis in proliferating lymphocytes and a panel of permanently transformed cell lines [105]. It has also showed potential benefit in a patient with pancreatic adenocarcinoma in a phase I clinical trial [106]. This evidence supported the evaluation of Didemnin B in phase II clinical trials in the U.S., being the first marine product to be approved.…”

Clovibactin: Discovery and antimicrobial mechanism of action

“…A relevant clinical aspect to be considered for its potential therapeutic application is the allergenic capacity of depsipeptides in comparison with conventional small molecule drugs. 5,6 In this regard, few immediate and non-immediate hypersensitivity reactions to different cyclic depsipetides, such as didemnin B, 7 pristinamycin IA, 8 and plitidepsin A, 9 have been reported. However, as some of these molecules are administered in combination with other drugs or excipients, in most cases it is unknown to which of the components the reaction is directed.…”

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

“…The first congener of this class, didemnin B, was isolated from the Caribbean tunicate Trididemnum solidum in 1981. Because of poor efficacy and many severe side effects such as anaphylactic reactions and neuromuscular toxicity in phase-I and II trials, its development was abandoned in favor of the second generation didemnin, plitidepsin, more active and better tolerated in clinical studies [154]. Plitidepsin shows in vitro and in vivo anti-tumor activity [35,155,156].…”

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds

“…Also, Didemnin B was found to induce apoptosis in proliferating lymphocytes and a panel of permanently transformed cell lines [105]. It has also showed potential benefit in a patient with pancreatic adenocarcinoma in a phase I clinical trial [106]. This evidence supported the evaluation of Didemnin B in phase II clinical trials in the U.S., being the first marine product to be approved.…”

Clovibactin: Discovery and antimicrobial mechanism of action

“…A relevant clinical aspect to be considered for its potential therapeutic application is the allergenic capacity of depsipeptides in comparison with conventional small molecule drugs. 5,6 In this regard, few immediate and non-immediate hypersensitivity reactions to different cyclic depsipetides, such as didemnin B, 7 pristinamycin IA, 8 and plitidepsin A, 9 have been reported. However, as some of these molecules are administered in combination with other drugs or excipients, in most cases it is unknown to which of the components the reaction is directed.…”

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

“…The first congener of this class, didemnin B, was isolated from the Caribbean tunicate Trididemnum solidum in 1981. Because of poor efficacy and many severe side effects such as anaphylactic reactions and neuromuscular toxicity in phase-I and II trials, its development was abandoned in favor of the second generation didemnin, plitidepsin, more active and better tolerated in clinical studies [154]. Plitidepsin shows in vitro and in vivo anti-tumor activity [35,155,156].…”